{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:03:51Z","timestamp":1777676631751,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","award":["43-349\/2014"],"award-info":[{"award-number":["43-349\/2014"]}],"id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002742","name":"Banaras Hindu University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019110","name":"Institute of Basic Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.pathol.2019.12.001","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:36:12Z","timestamp":1582590972000},"page":"348-358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["TRAIL receptors are differentially regulated and clinically significant in gallbladder cancer"],"prefix":"10.1016","volume":"52","author":[{"given":"Deepika","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-2666","authenticated-orcid":false,"given":"Chandra Bhushan","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipanjan","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mallika","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amrita Ghosh","family":"Kar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mumtaz Ahmed","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5851-9997","authenticated-orcid":false,"given":"Gopeshwar","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2019.12.001_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1084\/jem.20011171","article-title":"Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development","volume":"195","author":"Takeda","year":"2002","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.pathol.2019.12.001_bib2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.cdd.4401187","article-title":"Apo2L\/TRAIL and its death and decoy receptors","volume":"10","author":"LeBlanc","year":"2003","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.pathol.2019.12.001_bib3","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/cdd.2013.28","article-title":"Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family","volume":"20","author":"Azijli","year":"2013","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.pathol.2019.12.001_bib4","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/cdd.2014.81","article-title":"Getting TRAIL back on track for cancer therapy","volume":"21","author":"Lemke","year":"2014","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.pathol.2019.12.001_bib5","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3892\/or.2016.4839","article-title":"Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway","volume":"36","author":"Zhu","year":"2016","journal-title":"Oncol Rep"},{"key":"10.1016\/j.pathol.2019.12.001_bib6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ctrv.2008.11.006","article-title":"TRAIL receptor signalling and modulation: are we on the right TRAIL?","volume":"35","author":"Mahalingam","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.pathol.2019.12.001_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.214","article-title":"Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways","volume":"4","author":"van Dijk","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.pathol.2019.12.001_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1620\/tjem.217.203","article-title":"Over-expression of c-FLIP confers the resistance to TRAIL-induced apoptosis on gallbladder carcinoma","volume":"217","author":"Zong","year":"2009","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.pathol.2019.12.001_bib9","first-page":"967472","article-title":"Gallbladder cancer in the 21st century","volume":"2015","author":"Kanthan","year":"2015","journal-title":"J\u00a0Oncol"},{"key":"10.1016\/j.pathol.2019.12.001_bib10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1440-1746.2005.03576.x","article-title":"Gallbladder cancer in India: a dismal picture","volume":"20","author":"Batra","year":"2005","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.pathol.2019.12.001_bib11","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1245\/s10434-007-9539-9","article-title":"A\u00a0phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study","volume":"14","author":"Iyer","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.pathol.2019.12.001_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pathol.2019.12.001_bib13","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/s41467-017-01027-z","article-title":"Comprehensive analysis of normal adjacent to tumor transcriptomes","volume":"8","author":"Aran","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.pathol.2019.12.001_bib14","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1186\/s12885-018-4688-8","article-title":"Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC","volume":"18","author":"Gundlach","year":"2018","journal-title":"BMC Canc"},{"key":"10.1016\/j.pathol.2019.12.001_bib15","first-page":"3397","article-title":"Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors","volume":"9","author":"Spierings","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2019.12.001_bib16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11060-005-9081-1","article-title":"TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme","volume":"78","author":"Kuijlen","year":"2006","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.pathol.2019.12.001_bib17","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/ijc.24613","article-title":"TRAIL receptor upregulation and the implication of KRAS\/BRAF mutations in human colon cancer tumors","volume":"125","author":"Oikonomou","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pathol.2019.12.001_bib18","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.prp.2018.04.019","article-title":"Comprehensive expression analysis of TNF-related apoptosis-inducing ligand and its receptors in colorectal cancer: correlation with MAPK alterations and clinicopathological associations","volume":"214","author":"Tsikalakis","year":"2018","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.pathol.2019.12.001_bib19","first-page":"3734","article-title":"Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter","volume":"8","author":"Strater","year":"2002","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.pathol.2019.12.001_bib20","first-page":"2704","article-title":"Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5","volume":"61","author":"Mitsiades","year":"2001","journal-title":"Canc Res"},{"key":"10.1016\/j.pathol.2019.12.001_bib21","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00109-009-0510-z","article-title":"Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer","volume":"87","author":"Ganten","year":"2009","journal-title":"J\u00a0Mol Med"},{"key":"10.1016\/j.pathol.2019.12.001_bib22","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1158\/1078-0432.CCR-09-3403","article-title":"Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma","volume":"16","author":"Kriegl","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2019.12.001_bib23","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ijrobp.2007.03.057","article-title":"TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma","volume":"69","author":"Sanlioglu","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.pathol.2019.12.001_bib24","doi-asserted-by":"crossref","first-page":"36532","DOI":"10.1038\/srep36532","article-title":"Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer","volume":"6","author":"Devetzi","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.pathol.2019.12.001_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.351","article-title":"Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2","volume":"5","author":"Bertsch","year":"2014","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.pathol.2019.12.001_bib26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/hep.24698","article-title":"miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma","volume":"55","author":"Razumilava","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.pathol.2019.12.001_bib27","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1038\/onc.2010.235","article-title":"GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis","volume":"29","author":"Kurita","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.pathol.2019.12.001_bib28","doi-asserted-by":"crossref","first-page":"6617","DOI":"10.1074\/jbc.M112.448209","article-title":"Ubiquitination by the membrane-associated RING-CH-8 (MARCH-8) ligase controls steady-state cell surface expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) receptor 1","volume":"288","author":"van de Kooij","year":"2013","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.pathol.2019.12.001_bib29","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.4049\/jimmunol.164.8.3961","article-title":"Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells","volume":"164","author":"Zhang","year":"2000","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.pathol.2019.12.001_bib30","doi-asserted-by":"crossref","first-page":"43383","DOI":"10.1074\/jbc.M111.309377","article-title":"Importin beta 1 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5\/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells","volume":"286","author":"Kojima","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.pathol.2019.12.001_bib31","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.18632\/oncotarget.1174","article-title":"Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5","volume":"4","author":"Di","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.pathol.2019.12.001_bib32","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3109\/01443615.2014.889667","article-title":"Membrane expression of trail receptors DcR1 and DcR2 in the normal endometrium, endometrial atypical hyperplasia and endometrioid endometrial cancer","volume":"34","author":"Gottwald","year":"2014","journal-title":"J\u00a0Obstet Gynaecol"},{"key":"10.1016\/j.pathol.2019.12.001_bib33","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/sj.cdd.4400965","article-title":"Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells","volume":"9","author":"Bretz","year":"2002","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.pathol.2019.12.001_bib34","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12885-017-3259-8","article-title":"Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast Cancer","volume":"17","author":"Labovsky","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pathol.2019.12.001_bib35","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.leukres.2010.12.032","article-title":"High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2","volume":"35","author":"Chamuleau","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.pathol.2019.12.001_bib36","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1038\/srep04114","article-title":"Does DcR1 (TNF-related apoptosis-inducing-ligand Receptor 3) have any role in human AMD pathogenesis?","volume":"4","author":"Anand","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.pathol.2019.12.001_bib37","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.277.5327.815","article-title":"An antagonist decoy receptor and a death domain-containing receptor for TRAIL","volume":"277","author":"Pan","year":"1997","journal-title":"Science"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302520304591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302520304591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:19:48Z","timestamp":1777450788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302520304591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0031302520304591"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2019.12.001","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TRAIL receptors are differentially regulated and clinically significant in gallbladder cancer","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2019.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}